Phase | Study | Treatment arms | ClinicalTrials.gov identifier | Estimated primary completion date |
---|---|---|---|---|
First line | ||||
 II | REACTION | Cisplatin/carboplatin + etoposide + pembrolizumab vs. cisplatin/carboplatin + etoposide | NCT02580994 | August 2020 |
 III | CASPIAN | Durvalumab+ tremelimumab+ cisplatin/carboplatin + etoposide vs. durvalumab+ cisplatin/carboplatin + etoposide vs. cisplatin/carboplatin + etoposide | NCT03043872 | September 2019 |
Maintenance | ||||
 III | CheckMate-451 | Nivolumab vs. nivolumab + ipilimumab vs. placebo | NCT02538666 | October 2018 |
Relapsed | ||||
 I/II | CheckMate-331 | Nivolumab vs. topotecan vs. amrubicin | NCT02481830 | August 2018 |
 II | Winship3112-15 | Tremelimumab + durvalumab vs. tremelimumab + durvalumab + radiation | NCT02701400 | January 2020 |
 II | AFT-17 | Pembrolizumab vs. topotecan | NCT02963090 | May 2019 |
 I/II | CA001-030 | BMS-986012 vs. BMS-986012 ± nivolumab | NCT02247349 | October 2019 |
 I/II | MEDIOLA | Durvalumab + olaparib vs. durvalumab + olaparib + bevacizumab | NCT02734004 | March 2023 |